NAT2 and CYP2E1 polymorphisms and antituberculosis drug-induced hepatotoxicity in Peruvian patients.

Luis Jaramillo-Valverde Kelly S Levano David D Tarazona Silvia Capristano Roberto Zegarra Chapoñan Cesar SanchezVelia M Yufra-PicardoEduardo Martín Tarazona Santos Cesar Ugarte-Gil Heinner Guio

Published in: Molecular genetics & genomic medicine (2022)

We propose that the presence of NAT2 intermediate and CYP2E1 c1/c1 genotype could help in therapeutic drug monitoring, and optimize its therapeutic benefits while minimizing its risk for side effects or toxicity.

Keyphrases

drug induced
liver injury
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
oxide nanoparticles